Oral Minoxidil Year-1 Outcomes: What Real Users Actually Report

What do the first-year data look like?

The published studies report clinic measures such as hair counts, photographs, blood pressure and side effects rather than online user reports. A six-month randomized trial of 65 patients with androgenetic alopecia compared 1 mg daily oral minoxidil with 5% topical solution. Over 60% of patients in each group were satisfied, with no significant difference between groups [1]. The other studies below ran 24 weeks or are cohort or meta-analytic data [2][3][5][6].

What the studies measured

One single-arm, open-label study gave 30 men aged 24 to 59 with androgenetic alopecia oral minoxidil 5 mg daily for 24 weeks. Total hair count rose by a mean of 26 hairs/cm2 at week 12 and 35.1 hairs/cm2 at week 24. Vertex photographs were scored as improved in all 30, and 43% showed excellent improvement. Hypertrichosis occurred in 93% and pedal edema in 10%, with no serious cardiovascular adverse events [3].

A retrospective cohort of 1,404 patients treated for at least 3 months had no control group. Hypertrichosis was most frequent at 15.1% and led 14 patients (0.5%) to stop. Lightheadedness (1.7%), fluid retention (1.3%) and tachycardia (0.9%) came next, and 29 patients (1.2%) discontinued over systemic effects. No life-threatening effects were observed [2].

In a double-blind randomized trial, 90 men were given oral minoxidil 5 mg daily or topical 5% twice daily for 24 weeks, and 68 completed it. Between-group differences were not statistically significant: 3.1 hairs/cm2 for frontal terminal hair density (95% CI -18.2 to 21.5; P=.27) and 23.4 hairs/cm2 at the vertex (95% CI -0.3 to 43.0; P=.09) [6].

Blood pressure, heart rate and the label

A 2025 meta-analysis of low-dose oral minoxidil (5 mg/day or less) of uncontrolled studies found no significant change in systolic blood pressure (mean difference -0.13 mm Hg, 95% CI -2.67 to 2.41) or diastolic pressure. It did find a significant rise in heart rate of 2.67 beats per minute. Hypotensive symptoms were reported in 5.0% of patients, with no hypotensive episodes [5].

The oral tablet label covers a different use. Minoxidil tablets are approved only for hypertension not manageable with a diuretic plus two other antihypertensives, and the label states that use to promote hair growth, in any formulation, is not an approved indication. Its boxed warning on pericardial effusion and angina is written for antihypertensive doses, which start at 5 mg daily and usually run 10 to 40 mg daily [4].